berberine has been researched along with Osteoporosis in 12 studies
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "20-month-old male C57BL/6 J mice were used as senile osteoporosis mouse model and treated with strontium ranelate (SR) or berberine or solvent control by daily gavage for 2 months." | 8.02 | Protective effects of berberine on senile osteoporosis in mice. ( Bi, J; Chen, QC; Pu, YL; Zhang, Y, 2021) |
| "Osteoporosis was induced by bilateral ovariectomy." | 5.46 | Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017) |
| "Berberine may potentially retard the progression of osteoporosis, osteoarthritis and rheumatoid arthritis." | 5.05 | Berberine and musculoskeletal disorders: The therapeutic potential and underlying molecular mechanisms. ( Chin, KY; Ima-Nirwana, S; Wong, SK, 2020) |
| "20-month-old male C57BL/6 J mice were used as senile osteoporosis mouse model and treated with strontium ranelate (SR) or berberine or solvent control by daily gavage for 2 months." | 4.02 | Protective effects of berberine on senile osteoporosis in mice. ( Bi, J; Chen, QC; Pu, YL; Zhang, Y, 2021) |
| "Berberine (BBR) has recently been reported to be extensively used for musculoskeletal disorders such as osteoporosis through enhancing osteogenic differentiation, inhibiting osteoclastogenesis and bone resorption and repressing adipogenesis." | 3.83 | Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway. ( Kang, B; Tao, K; Weng, J; Xiao, D; Xiong, A; Zeng, H, 2016) |
| "Berberine is a compound for which both antidiabetic and antiosteoporotic effects have been documented." | 1.72 | Lack of berberine effect on bone mechanical properties in rats with experimentally induced diabetes. ( Cegieła, U; Folwarczna, J; Gajdoš, M; Janas, A; Kisiel-Nawrot, E; Kocik, S; Krivošíková, Z; Londzin, P; Skoczyńska, A; Štefíková, K, 2022) |
| "Osteoporosis is a common disorder of bone remodeling, marked by excessive osteoclast formation." | 1.51 | Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression. ( Han, SY; Kim, YK, 2019) |
| "Berberine has been implicated to be involved in maintaining bone health due to its anti-oxidative and osteogenic properties." | 1.48 | Berberine derivative, Q8, stimulates osteogenic differentiation. ( Han, Y; Kim, MJ; Lee, KY, 2018) |
| "Pioglitazone treatment significantly increased urinary calcium, serum TRAP, mRNA expression of RANKL, PPAR-γ as well as significantly decreased Runx2, OPG, osteocalcin and AMPK levels in diabetic rats." | 1.46 | Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk. ( Adil, M; Kandhare, AD; Mansoori, MN; Sharma, M; Singh, D, 2017) |
| "Osteoporosis was induced by bilateral ovariectomy." | 1.46 | Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. ( Dai, Z; Guo, MF; He, XF; Li, H; Sui, FG; Tian, GF; Zhang, CH; Zhang, L; Zhang, LF; Zhao, CR, 2017) |
| "Berberine is an isoquinoline alkaloid widely used in Asian countries as a traditional medicine." | 1.38 | Possible therapeutic potential of berberine in diabetic osteopathy. ( Bhutada, PS; Kaulaskar, SV; Rahigude, AB, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Londzin, P | 1 |
| Kocik, S | 1 |
| Kisiel-Nawrot, E | 1 |
| Janas, A | 1 |
| Skoczyńska, A | 1 |
| Krivošíková, Z | 1 |
| Štefíková, K | 1 |
| Gajdoš, M | 1 |
| Cegieła, U | 1 |
| Folwarczna, J | 1 |
| Chen, QC | 1 |
| Pu, YL | 1 |
| Bi, J | 1 |
| Zhang, Y | 1 |
| Adil, M | 1 |
| Mansoori, MN | 1 |
| Singh, D | 1 |
| Kandhare, AD | 1 |
| Sharma, M | 1 |
| He, XF | 1 |
| Zhang, L | 1 |
| Zhang, CH | 1 |
| Zhao, CR | 1 |
| Li, H | 2 |
| Zhang, LF | 1 |
| Tian, GF | 1 |
| Guo, MF | 1 |
| Dai, Z | 1 |
| Sui, FG | 1 |
| Han, Y | 1 |
| Kim, MJ | 1 |
| Lee, KY | 1 |
| Xie, H | 1 |
| Wang, Q | 1 |
| Zhang, X | 1 |
| Wang, T | 1 |
| Hu, W | 1 |
| Manicum, T | 1 |
| Chen, H | 1 |
| Sun, L | 1 |
| Han, SY | 1 |
| Kim, YK | 1 |
| Wong, SK | 1 |
| Chin, KY | 1 |
| Ima-Nirwana, S | 1 |
| Tao, K | 1 |
| Xiao, D | 1 |
| Weng, J | 1 |
| Xiong, A | 1 |
| Kang, B | 1 |
| Zeng, H | 1 |
| Xu, D | 1 |
| Yang, W | 1 |
| Zhou, C | 1 |
| Liu, Y | 1 |
| Xu, B | 1 |
| Rahigude, AB | 1 |
| Kaulaskar, SV | 1 |
| Bhutada, PS | 1 |
| Miyahara, T | 1 |
| Tezuka, Y | 1 |
| Tran, QL | 1 |
| Seto, H | 1 |
| Kadota, S | 1 |
1 review available for berberine and Osteoporosis
| Article | Year |
|---|---|
Berberine and musculoskeletal disorders: The therapeutic potential and underlying molecular mechanisms.
Topics: Animals; Arthritis, Rheumatoid; Berberine; beta Catenin; Humans; Musculoskeletal Diseases; NF-kappa | 2020 |
11 other studies available for berberine and Osteoporosis
| Article | Year |
|---|---|
Lack of berberine effect on bone mechanical properties in rats with experimentally induced diabetes.
Topics: Animals; Berberine; Bone Density; Bone Remodeling; Diabetes Mellitus, Experimental; Diabetes Mellitu | 2022 |
Protective effects of berberine on senile osteoporosis in mice.
Topics: Animals; Berberine; Cell Differentiation; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Os | 2021 |
Pioglitazone-induced bone loss in diabetic rats and its amelioration by berberine: A portrait of molecular crosstalk.
Topics: Animals; Berberine; Biomarkers; Blood Glucose; Bone and Bones; Bone Density; Diabetes Mellitus, Expe | 2017 |
Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.
Topics: Animals; Antioxidants; Berberine; Body Weight; Bone Density; Female; Femur; NF-kappa B; Osteoporosis | 2017 |
Berberine derivative, Q8, stimulates osteogenic differentiation.
Topics: Animals; Berberine; Cell Differentiation; Cell Line; Glycogen Synthase Kinase 3 beta; Mice; Myoblast | 2018 |
Possible therapeutic potential of berberine in the treatment of STZ plus HFD-induced diabetic osteoporosis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Berberine; Blood Glucose; Body Weight; Bone Density; Deoxyguan | 2018 |
Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
Topics: Animals; Berberine; Cell Differentiation; Cells, Cultured; Gene Expression; Male; Mice, Inbred ICR; | 2019 |
Berberine promotes bone marrow-derived mesenchymal stem cells osteogenic differentiation via canonical Wnt/β-catenin signaling pathway.
Topics: Alkaline Phosphatase; Berberine; beta Catenin; Bone Marrow; Cell Differentiation; Cell Survival; Cor | 2016 |
Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Berberine; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation | 2010 |
Possible therapeutic potential of berberine in diabetic osteopathy.
Topics: Berberine; Calcitonin; Diabetes Complications; Glucagon-Like Peptides; Glycation End Products, Advan | 2012 |
Effect of berberine on bone mineral density in SAMP6 as a senile osteoporosis model.
Topics: Aging; Animals; Berberine; Bone Density; Disease Models, Animal; Female; Hydrastis; Male; Mice; Mice | 2003 |